Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Urethral Cancer: early-phase trial registry

3 of 9 indexed Urethral Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Urethral Cancer: 9 US clinical trials tracked, 3 recruiting.

Urethral Cancer is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Eastern Cooperative Oncology Group, running 2 of these trials.

Enrollment posture brief

Registry condition urethral-cancer

OPEN 3 | RECR 33% | LATE 0 | EARLY 6 | RANK #1916 | SPON 2

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Urethral Cancer (this)33%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Urethral Cancer

Urethral Cancer lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Urethral Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Urethral Cancer is recruiting below its size-band peers.

    3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Urethral Cancer research.

    Eastern Cooperative Oncology Group accounts for 2 of 9 trials (22.2%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Urethral Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 46 among the 8 trials that report a genuine target (sentinel values excluded). 7 of those (87.5%) plan for fewer than 100 participants.

  4. Urethral Cancer research is mostly interventional.

    8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 1 91 participants

64Cu-GRIP B in Patients With Advanced Malignancies

Rahul Aggarwal

NCT05888532

RECRUITING 16 participants

Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

Fox Chase Cancer Center

NCT03291028

RECRUITING NA 10 participants

A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest

Dana-Farber Cancer Institute

NCT05899361

ACTIVE NOT RECRUITING Phase 1 80 participants

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

M.D. Anderson Cancer Center

NCT00479128

ACTIVE NOT RECRUITING Phase 2 46 participants

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

M.D. Anderson Cancer Center

NCT00082706

COMPLETED NA 219 participants

UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch

Matthew Milowsky, MD

NCT02643043

COMPLETED Phase 2 46 participants

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Eastern Cooperative Oncology Group

NCT00053209

COMPLETED Phase 2 31 participants

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

SWOG Cancer Research Network

NCT00014144

COMPLETED Phase 2

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

Eastern Cooperative Oncology Group

NCT00004223

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4

Named interventions

Most-linked intervention names on Urethral Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

gemcitabine hydrochloride Drug
2 trials
Gemcitabine Drug
2 trials
gefitinib Drug
1 trials
pemetrexed disodium Drug
1 trials
Electromagnetic Guided Laparoscopy Device
1 trials
Copper-64 labeled Granzyme B (64Cu-GRIP B) Drug
1 trials
Positron Emission Tomography (PET) Procedure
1 trials
docetaxel Drug
1 trials

US sites by state

Facility locations filed on Urethral Cancer trials. A trial with sites in several states counts in each.

California 4 trials
Texas 2 trials
Pennsylvania 2 trials
Illinois 2 trials
Georgia 2 trials
Florida 2 trials
Delaware 2 trials
Colorado 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Urethral Cancer page

9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Urethral Cancer condition card totals 9 registered trials; most-linked intervention gemcitabine hydrochloride; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.